Lisdexamfetamine (Elvanse / XURTA) — the amphetamine finally arriving in France

One molecule, several names

You may have heard Vyvanse, Elvanse, Tyvense. Since 2025 in France, there’s also XURTA ^[2] . These four names all refer to the same active ingredient: lisdexamfetamine (LDX).

• Vyvanse: US and Canada brand name (Takeda).
• Elvanse: UK, Germany, other European countries brand name (Takeda).
• Tyvense: Ireland.
• XURTA: France, since September 2025 (HAC Pharma laboratory, not Takeda).

What it is, chemically

Lisdexamfetamine is a prodrug — an inactive molecule until it’s metabolised. In the blood, red blood cells enzymatically cleave it into L-lysine + dexamfetamine (the active form, pure dextroamphetamine).

This progressive metabolisation explains lisdexamfetamine’s three distinctive features:

Mechanism of action

Once metabolised, dexamfetamine ^[7] :

• Inhibits the reuptake of dopamine and noradrenaline (like methylphenidate).
• But also actively triggers release of these neurotransmitters from pre-synaptic vesicles (action on VMAT2).
• Result: synaptic concentration increased via two distinct routes.

That’s why the subjective profile can differ from methylphenidate — and why a person who doesn’t respond to methylphenidate can respond to amphetamines (and vice versa).

What the evidence says — efficacy

International data

• Cortese 2018 (Lancet Psychiatry) ^[6] : amphetamines (including LDX) are superior to methylphenidate on efficacy in adults. With lower tolerability — more adverse effects leading to discontinuation.
• Gosling, Cortese et al. 2025 (BMJ) ^[5] : at least moderate-certainty evidence for amphetamines in adults (restricted to high-quality studies). Medium-to-large effect.
• Farhat 2024 ^[8] : off-label doses of amphetamines don’t provide additional clinically relevant benefit and increase dropouts.

Typical trajectory

The French framework — a complicated French history

The long compassionate access period

For more than 10 years, lisdexamfetamine had no French marketing authorisation, even though it was authorised in most European countries. French patients who benefited from it had access via the compassionate mechanism (formerly ATU, then AAC since 2021) ^[3] , under Takeda’s responsibility.

Indication for AAC (restrictive):

• ADHD adult with symptoms present since childhood.
• Insufficient response or intolerance to methylphenidate.

Cumbersome procedure, limited access, and reimbursement not guaranteed.

The XURTA marketing authorisation in 2025 — what changes

HAS verdict:

• SMR (Medical Service Rendered): moderate.
• ASMR (Improvement of Medical Service Rendered): level V — no improvement over methylphenidate.
• Role in therapeutic strategy: second-line in adults, when methylphenidate response is insufficient or it isn’t tolerated.

Translation: for HAS, XURTA isn’t a revolutionary treatment that outperforms methylphenidate. It’s a useful alternative when methylphenidate doesn’t fit.

Prescribing conditions

Identical to methylphenidate ^[2] :

• Secure prescription (Schedule I, controlled substance).
• Initial prescribing restricted to a specialist: psychiatrist, neurologist, paediatrician (community or hospital).
• Prescription duration 28 days, non-renewable.
• Monthly renewals possible by any doctor, annual renewal by specialist.
• Designated pharmacy on the prescription.

Access via Elvanse (compassionate) still possible?

Yes, but restricted. Compassionate access to Elvanse (Takeda) remains in force ^[3] , notably for doses not covered by XURTA (50 mg, 60 mg, 70 mg) or in case of shortage. But the arrival of XURTA will probably reshape this framework. Access remains via the e-Saturne platform.

Who is lisdexamfetamine indicated for?

The situations where it’s offered

Contraindications and reinforced precautions

Side effects

Profile comparable to other stimulants, with a few nuances:

Common

• Decreased appetite — often more marked with amphetamines, sometimes more than methylphenidate.
• Weight loss — active weight monitoring recommended.
• Sleep-onset insomnia — mandatory morning dosing, avoid late intake.
• Dry mouth.
• Headaches, dizziness.
• Slight increase in heart rate and blood pressure.
• Anxiety, nervousness.

Less common

• Sweating, flushing.
• Bruxism.
• Reduced libido, erectile issues.
• Irritability, mood swings.

Rare but serious

Same as methylphenidate: chest pain, priapism, psychotic phenomena, suicidal ideation. Immediate reporting to prescriber.

The question of diversion and abuse

Sensitive point. Amphetamines are classified controlled substances (Schedule II in the US, Schedule I in France). They have non-zero abuse potential.

What reduces risk with LDX

• Prodrug form: inactive if snorted, smoked, injected.
• Slow ramp-up → less euphoric “rush”.
• Long duration → no need to re-dose during the day.

What remains a real risk

• Consumed orally at supratherapeutic doses, it can be diverted.
• Dangerous combinations: alcohol, cocaine, MDMA, other stimulants.
• History of substance use disorder = red flag.

The clinical consensus ^[7] : treating ADHD in people with a history of abuse on average reduces the risk of future consumption, because untreated ADHD is itself a vulnerability factor. But individual assessment remains essential.

The conversation with your psychiatrist

If you’re considering lisdexamfetamine:

Methylphenidate didn’t suit me — too short, too many peaks and crashes. Elvanse changed everything. One morning dose and the day holds up. The arrival of XURTA at the local pharmacy is mostly an administrative relief — no more going through compassionate access.

Honest questions we rarely ask

”Is it better than methylphenidate?”

Not in general, and not for HAS ^[1] (ASMR V = no improvement). For some people, yes. For others no. Responding to methylphenidate doesn’t predict response to amphetamines — these are two different pharmacologies.

”Can I ask for lisdexamfetamine right away?”

In France, HAS recommends methylphenidate first-line in adults and lisdexamfetamine second. If your psychiatrist respects this framework, you’ll go through methylphenidate first. It’s a pragmatic rule (cost, clinical experience) more than an efficacy hierarchy.

”What if my psychiatrist doesn’t know XURTA?”

That’s a risk in 2026. The product is new in France. Specialists trained in adult ADHD should normally be aware. If not — HyperSupers TDAH France has resources, and you can ask to see a more up-to-date colleague.

Signals for emergency consultation

Takeaways

Go further

• Methylphenidate (Ritaline, Concerta) — first choice in France
• Atomoxetine (Strattera) — when stimulants don’t fit
• ADHD medication shortages in France — practical guide
• Managing side effects — practical guide
• The diagnostic pathway